Local and central testing for HER2, PD-L1, MSI/MMR, EBV, and CLDN18.2 in advanced gastric cancer: results from the SAPHIR registry
晚期胃癌中HER2、PD-L1、MSI/MMR、EBV和CLDN18.2的局部和中心检测:来自SAPHIR注册研究的结果
期刊:
影响因子:
doi:10.1016/j.esmorw.2025.100144
Potthoff, K; Bläker, H; Dechow, T; Binninger, A; Ringwald, K; de Buhr, R; von der Heyde, E; Zahn, M-O; Nusch, A; Dörfel, S; Schulz, H; Haffner, I; Höhn, A K; Monecke, A; Lorenzen, S; Reinacher-Schick, A; Jänicke, M; Lordick, F
胃癌
CLDN1
肿瘤
HER2
多发性骨髓瘤
肿瘤免疫
多发性硬化症
PD-L1